Maria Pia Brizzi
Overview
Explore the profile of Maria Pia Brizzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, et al.
Eur J Cancer
. 2024 Jul;
208:114129.
PMID: 39002347
Background: Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy is currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies....
2.
Panzuto F, Andrini E, Lamberti G, Pusceddu S, Rinzivillo M, Gelsomino F, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610840
The optimal treatment sequencing for advanced, well-differentiated pancreatic neuroendocrine tumors (pNETs) is unknown. We performed a multicenter, retrospective study to evaluate the best treatment sequence in terms of progression-free survival...
3.
Stumpo S, Formelli M, Persano I, Parlagreco E, Lauricella E, Rodriquenz M, et al.
J Clin Med
. 2023 Dec;
12(24).
PMID: 38137784
Neuroendocrine carcinomas (NECs) are poorly differentiated and highly aggressive epithelial neuroendocrine neoplasms. The most common primary site is the lung, but they may arise in every organ. Approximately 37% of...
4.
La Salvia A, Siciliani A, Rinzivillo M, Verrico M, Baldelli R, Puliani G, et al.
Endocrine
. 2023 Sep;
83(2):519-526.
PMID: 37775725
Purpose: Thyroid transcription factor-1 (TTF-1) assessed by immunohistochemistry (IHC) is a specific biomarker for lung adenocarcinoma, and is commonly used to confirm the pulmonary origin of neuroendocrine tumours (NET). The...
5.
Corti F, Brizzi M, Amoroso V, Giuffrida D, Panzuto F, Campana D, et al.
BMC Cancer
. 2023 Sep;
23(1):908.
PMID: 37752423
Background: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET...
6.
Persano I, Parlagreco E, La Salvia A, Audisio M, Volante M, Buttigliero C, et al.
Semin Oncol
. 2023 Feb;
49(6):476-481.
PMID: 36759234
The simultaneous or metachronous occurrence of pancreatic neuroendocrine tumor (panNET) and renal cell carcinoma (RCC) may represent a rare coincidence or a manifestation of von Hippel-Lindau disease (VHL). These two...
7.
Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D, et al.
J Clin Med
. 2023 Jan;
12(2).
PMID: 36675645
Neuroendocrine tumors (NETs) are rare neoplasms with a wide spectrum of clinical behavior, from the long survival of well-differentiated NETs to the dismal prognosis of high-grade neuroendocrine carcinomas (NECs), being...
8.
Trevisi E, Facilissimo I, Taraglio S, Brizzi M
J Cancer Res Ther
. 2022 Sep;
18(4):1171-1173.
PMID: 36149180
Mesenteric fibromatosis (desmoid tumor) is a locally aggressive fibroblastic lesion, characterized by a high recurrence rate that makes treatment challenging. Currently, there is no evidence-based treatment approach. We report the...
9.
Ferolla P, Berruti A, Spada F, Brizzi M, Ibrahim T, Marconcini R, et al.
Neuroendocrinology
. 2022 Aug;
113(3):332-342.
PMID: 36044870
Introduction: Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking. ATLANT (NCT02698410) evaluated efficacy...
10.
La Salvia A, Persano I, Parlagreco E, Audisio A, Cani M, Brizzi M
Med Oncol
. 2022 Aug;
39(11):168.
PMID: 35972607
Pancreatic adenocarcinoma is the seventh leading cause of cancer death in the world and the most common type pf pancreatic cancer. Unfortunately, less than 20% of patients are surgically resectable...